- Home
- SABR vs MYGN Comparison
SABR vs MYGN Comparison
Compare SABR & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SABR | MYGN |
|---|---|---|
| Founded | 2006 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 627.9M | 625.5M |
| IPO Year | 2014 | 1995 |
Fundamental Metrics
Financial Performance| Metric | SABR | MYGN |
|---|---|---|
| Price | $1.65 | $7.33 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 5 | 13 |
| Target Price | $4.12 | ★ $12.58 |
| AVG Volume (30 Days) | ★ 5.4M | 1.1M |
| Earning Date | 11-05-2025 | 11-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.41 | N/A |
| Revenue | ★ $3,034,040,000.00 | $825,300,000.00 |
| Revenue This Year | N/A | $0.10 |
| Revenue Next Year | $3.88 | $5.28 |
| P/E Ratio | $1.18 | ★ N/A |
| Revenue Growth | ★ 8.86 | 0.21 |
| 52 Week Low | $1.52 | $3.76 |
| 52 Week High | $4.63 | $16.83 |
Technical Indicators
Market Signals| Indicator | SABR | MYGN |
|---|---|---|
| Relative Strength Index (RSI) | 45.08 | 52.17 |
| Support Level | $1.57 | $6.93 |
| Resistance Level | $1.64 | $8.09 |
| Average True Range (ATR) | 0.08 | 0.41 |
| MACD | 0.01 | 0.06 |
| Stochastic Oscillator | 65.96 | 59.67 |
Price Performance
Historical ComparisonAbout SABR Sabre Corporation
Sabre holds the number-two air booking volume share in the global distribution system industry. The travel solutions segment represented 91% of total 2024 revenue, split between distribution (79% of segment sales) and airline IT solutions (21%) revenue. The company sold its growing hotel IT solutions division (9% of revenue) to TPG in 2025 for $960 million in net proceeds. Transaction fees, which are mostly tied to volume and not price, account for the bulk of sales and profits.
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.